Satavaptan

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameSatavaptan
Drug Alias Name沙伐普坦satavaptanum沙他伐坦satavaptan萨特普坦 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVasopressin V2 receptor antagonists
TargetsVasopressin V2 receptor
Therapy Area/IndicationsAscitesHyponatremiaHeart Failure +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[36] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi
Active IndicationsN/A
Inactive IndicationsAscitesHyponatremiaHeart Failure +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia